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ABSTRACT 
Objective: In systemic sclerosis (SSc), pulmonary function tests (PFTs) have been 
included in screening algorithms for pulmonary hypertension (PH).  However, in 
combined pulmonary fibrosis and emphysema (CPFE), the interpretation of PFT is 
confounded.   We examined the prevalence of CPFE in SSc patients with interstitial 
lung disease (SSc-ILD) and the effect of CPFE on PFTs used to evaluate the severity 
of SSc-ILD and the likelihood of PH. 
Methods: HRCT scans of 333 SSc-ILD patients were evaluated for the presence of 
emphysema, extent of interstitial lung disease. The effects of emphysema were 
quantified on relationships between pulmonary function variables and a) the extent of 
SSc-ILD on HRCT; and b) echocardiographic evidence of PH. 
Results: Emphysema was present in 41/333 cases overall (12.3%), in 26/132 smokers 
(19.7%) and in 15/201 life-long non smokers (7.5%).  With the extent of fibrosis 
taken into account, emphysema was associated with signficant additional changes 
from expected values in DLco (- 24.1%, p<0.0005), pO2, (p=0.04), and FVC/DLco (+ 
34.8%, p<0.0005) but not in FVC.  These effects were identical in smokers and non-
smokers. On multivariate analysis, the presence of emphysema had a greater effect 
than echocardiographic PH on FVC/DLco, whether analysed as a continuous variable 
or using thresholds of 1.6 or 2.0.  
Conclusion: In SSc-ILD, emphysema is sporadically present in non-smokers and is 
associated with a low pack-year smoking history in smokers.  The confounding effect 
3 
 
of CPFE on measures of gas exchange has major implications for the construction of 
screening algorithms for PH in SSc-ILD.   
INTRODUCTION 
In systemic sclerosis (SSc), pulmonary involvement (including interstitial lung 
disease and pulmonary hypertension [PH]) is the most common cause of death (1). 
Interstitial lung disease in SSc [SSc-ILD] ranges from sub-clinical lung involvement 
to major pulmonary disease progressing to respiratory failure and death (2).  The 
severity of SSc-ILD is most frequently quantified in routine practice using 
pulmonary function tests.  Carbon monoxide diffusing capacity (DLco) levels best 
reflect the morphologic extent of SSc-ILD on high resolution computed tomography 
(HRCT) (3) but are also profoundly affected by presence of PH.  More recently, an 
increased FVC/DLco ratio has been advocated as a determinant of which SSc patients 
should undergo echocardiographic screening for PH ( 4-7).   
There is reason to suspect that concurrent emphysema may seriously confound 
pulmonary function tests in SSc-ILD.  In idiopathic pulmonary fibrosis (IPF), 
concurrent emphysema has been associated with spurious preservation of forced vital 
capacity (FVC) levels, devastating reductions in DLco levels (8) and, by implication, 
major effects on FVC/DLco ratios.  Parallel analyses have yet to be performed in 
suitably large cohorts of SSc-ILD patients, despite the fact that the combination of 
pulmonary fibrosis and emphysema (CPFE) occurs in SSc (9).      
Therefore, the aims of our study were a) to examine the prevalence of emphysema in 
a large SSc-ILD cohort and b) to determine whether the presence of emphysema has a 
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major confounding effect on pulmonary function tests used to evaluate interstitial 
lung disease severity and the likelihood of PH in SSc-ILD. 
 
PATIENTS and METHODS 
Methods 
The study population consisted of 333 patients with SSc-ILD, referred between 
January 1990 and October 2004 (age 54.4 + 13.1 years, 262 females), fulfilling the 
American College of Rheumatology criteria for systemic sclerosis (10), with no 
overlap features.  During this time period, our major rheumatological collaborators 
referred unselected patients with known or suspected SSc-ILD.  After October 2004, 
this policy was changed to one of referral of selected patients.  The diagnosis of SSc-
ILD was based on evidence of interstitial lung disease on HRCT.  Exclusion criteria 
consisted of a) the performance of HRCT scans elsewhere, unavailable for scoring; b) 
the separation of baseline HRCT and PFT by more than 90 days and c) smoking 
history not recorded (n=3). These exclusions apart, the cohort was consecutive and 
investigations were performed as part of a prospective clinical protocol.  Baseline 
data are shown in Tables 1 and 2: analyses of serological status were confined to 
patients undergoing testing at presentation in the same laboratory (n=308). 
Clinical data 
“Ever smokers” had smoked at least one cigarette per day for at least one year.  Pack-
year smoking histories were recorded.  In three cases, the smoking history was 
considered to be unreliable: these patients were excluded from the analyses.  
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Pulmonary function tests, echocardiography and HRCT were performed as previously 
reported (11-12).   
Echocardiographic evaluation included estimation of pulmonary arterial systolic 
pressure from tricuspid regurgitant jet velocity, the identification of right ventricular 
or right atrial enlargement, and the evaluation of right ventricular function.   
Echocardiographic pulmonary hypertension was defined as a pulmonary arterial 
systolic pressure of 40 mm Hg or greater. Echocardiography was routinely 
performed at presentation: 25 of 333 patients not undergoing echocardiography at our 
institution were excluded from echocardiographic analyses.      
HRCT sections (1.5mm - 3mm) were acquired supine, at full inspiration, at 10mm 
intervals (window center = -550 Hounsfield units (HU); window width = 1500 HU), 
using an electron beam scanner (Imatron Inc., San Francisco, CA).  Scans were scored 
independently by two observers (AUW and SRD), blinded to clinical and lung 
function information.  HRCT features were scored as five levels, defined using 
anatomical landmarks, as described previously (13-14), as follows: 
- The extent of interstitial lung disease was estimated to the nearest five percent 
in each section, with global extent of disease on HRCT computed as the mean 
of the scores for section.  Discrepancies of more than 20% in global scores 
were resolved by consensus. 
- The extent of emphysema was estimated to the nearest five percent in each 
section, with global extent of disease on HRCT computed as the mean of the 
scores for section.  Disagreement on the presence or absence of emphysema 
and discrepancies of more than 20% in global scores were resolved by 
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consensus. To be scored as present, emphysema was required to be 
separate geographically from interstitial fibrosis.  Two patients, in whom 
there was limited emphysematoid destruction within fibrotic lung, with 
no additional emphysema in other lung regions, were scored as not having 
emphysema. 
- The distributions of interstitial lung disease and emphysema were 
quantified as upper zone extent/(upper + lower zone extent), adjusted to a 
percentage value.  Upper zone extent was computed as the average extent 
of disease in the two uppermost sections.  Lower zone extent was 
computed as the average extent of disease in the three lowermost sections.   
Data analysis 
Analyses were performed using STATA software (Stata data analysis software; 
Computing Resource Centre, Santa Monica, CA). Data were expressed as means (SD) 
or medians (range), depending on distribution. Group comparisons were made using 
Student’s t test, Wilcoxon rank sum, chi-squared statistics and Fisher’s exact test, as 
appropriate. A p-value of <0.05 was considered significant.  Inter-observer variation 
was quantified as the kappa coefficient of agreement for the presence of emphysema 
and the single-determination standard deviation for a) the extent of interstitial lung 
disease; and b) the extent of emphysema.  
Correlations between the extent of interstitial lung disease and individual PFTs were 
examined using Pearson’s product moment correlation.   Univariate and multivariate 
analyses were performed.  Logistic regression was used to identify independent 
associations with a) the presence of emphysema; and b) FVC/DLco threshold values 
of  >1.6 and >2.0.   Multiple linear regression models were constructed to identify the 
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independent determinants of levels of individual PFT.  Models were formally tested 
for heteroscedasticity to confirm that the assumptions of parametric analysis had been 
satisfied.    
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RESULTS 
Inter-observer variation for HRCT observations   
Agreement was good for the presence of emphysema (kappa coefficient of agreement 
= 0.64).  The single determination standard deviation for the extent of interstitial lung 
disease was 4.1%. 
Sub-group differences: the presence of emphysema and smoking status 
 
Baseline data are compared between patients with and without CPFE in Table 1. 
CPFE was present in 41/336 cases (12.2%) and was more prevalent in smokers 
(26/132, 19.7%) than in non-smokers (15/201, 7.5%), p<0.001, and in males 
(18/74, 24%) than in females (23/259, 9%), p<0.0005.  In life-long nonsmokers, 
CPFE was more prevalent in males (5/26, 33%) than in females (10/175, 6%, 
p=0.01).  Patients with CPFE were characterized by greater impairment of gas 
exchange and gas transfer, a higher FVC/DLco ratio and a median extent of 
emphysema of 5.5% (range 1-30%).   
Baseline data are compared between smokers and non-smokers in Table 2.  
When compared with life-long non-smokers, ever–smokers were older and more 
frequently male. The extent of emphysema (when present) did not differ between 
smokers (5.75%, range 1-30%) and non-smokers (median 5.5%, range 1 to 
28.5%), p=0.74.  The median smoking dose associated with the presence of 
emphysema in smokers (in 23 of 26 patients with exact quantification of the 
smoking dose) was 25 pack years (range 2 to 40 pack years).  Logistic regression 
showed that after adjustment for age and gender, the presence of emphysema 
was positively linked to the pack year smoking dose, both in the whole 
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population (odds ratio 1.05, 95% CI 1.02, 1.08, p<0.0005) and in ever-smokers 
(odds ratio 1.04, 95% CI 1.00, 1.07, p=0.04).   
Upper zone emphysema was more extensive on average than lower zone 
emphysema on paired t-testing (13.9 ± 11.3 versus 4.7 ± 6.5; p<0.00005) and was 
more extensive than lower zone emphysema in all but one case.  The extent of 
interstitial lung disease was not linked either to the extent of emphysema (Rs = -
0.06, p=0.72) or the proportion of emphysema in the upper zone (Rs = -0.02, 
p=0.88).  The distribution of emphysema did not differ between smokers and 
non-smokers.  
 
The effect of emphysema and smoking status on pulmonary function variables 
The extent of interstitial lung disease on HRCT was negatively related to % predicted 
DLco (R = -0.56), % predicted FVC (R = -0.35), % predicted FEV1 (R = -0.28), pO2 
(R = -0.45) and positively related to the calculated alveolar arterial oxygen gradient 
(R = 0.40), all p<0.0005.  
As shown in Table 3, the extent of interstitial lung disease and the presence of 
emphysema were independent determinants of % predicted DLco levels. 
Smoking status provided no independent linkage to DLco levels whether 
quantified as “ever/never smoking” or as the pack-year smoking history.   These 
findings did not change with the exclusion of current smokers: the determinants 
of DLco were ILD extent (RC-0.59; 95%CI -0.69, -0.49; p<0.0005) and the 
presence of emphysema (RC-12.2; 95%CI -17.7, -6.7; p<0.0005) with no 
independent link to smoking status (RC-2.1; 95%CI-5.5, 1.3; p=0.22).  
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The effect of emphysema, a reduction in DLco of 12.4%, represented, on average, a 
24.1% reduction from the mean observed value of 51.4%. The negative effect of 
emphysema on DLco levels, after adjustment for the extent of interstitial lung disease, 
is shown in Figure 1 and was seen both in ever-smokers (RC = -11.2; 95% CI-17.6, -
4.8; p<0.001) and non-smokers (RC = -13.9; 95% CI = -21.4, -6.3; p<0.0005) in 
separate models. The presence of emphysema had a lesser impact on DLco levels 
when emphysema was limited (CT extent<5%; RC-8.6; 95%CI -16.2, -1.1; 
p=0.03) than when it more extensive (CT extent>5%; RC-14.0; 95%CI -20.7, -
9.0; p<0.0005). 
 In 311 patients undergoing concurrent echocardiography, the extent of interstitial 
lung disease, the presence of emphysema and the presence of pulmonary hypertension 
were independent negative determinants of % predicted DLco levels.   
The independent effects of the extent of interstitial lung disease, the presence of 
emphysema and smoking status (current/former smokers versus lifelong non-smokers) 
upon other pulmonary function variables are shown in Table 2 (with adjustment for 
age and gender).  Indices of gas exchange (pO2 levels, the alveolar-arterial oxygen 
gradient) were more strongly influenced by the presence of emphysema than by the 
smoking status.  By contrast, the presence of emphysema had no independent effect 
on FEV1 or FVC levels (Figure 2), whereas current or former smokers exhibited 
relative preservation of spirometric volumes.  
 There was no association between the presence of emphysema and auto-
antibody status (ATA positivity versus non-ATA-positivity). The inclusion of 
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ATA status (ATA-positivity versus ATA negativity) in the multivariate model 
established that this serological distinction had no independent effect (p=0.51) on 
the linkage between emphysema and pulmonary function variables, with no 
evidence of an interaction.  
The determinants of the FVC/DLco ratio 
FVC/DLco ratios were positively correlated with the extent of disease on HRCT (R = 
0.36, p<0.0005). FVC/DLco ratios were higher in patients with PH on 
echocardiography (median 1.86, range 0.99 to 3.55) than in those without PH (median 
1.42, range 0.73 to 3.40), p<0.0001.  FVC/DLco ratios were higher in patients with 
emphysema (median 2.07, range 1.14 to 3.42) than in patients without emphysema 
(median 1.42, range 0.73 to 3.55), p<0.0001.    
On multiple linear regression (after adjustment for age and gender), the independent 
determinants of the FVC/DLco ratio were HRCT disease extent (RC = 0.009; 95% CI 
0.006, 0.011; p<0.0005), the presence of emphysema (RC = 0.55, 95% CI 0.41, 0.69; 
p<0.0005), the presence of PH on echocardiography (RC = 0.25; 95% 0.11, 0.38, 
p<0.0005) and smoking status (RC = 0.13; 95% CI 0.03, 0.22; p<0.01) (Table 4).  
These findings were unchanged when analysis was confined to 211 patients with 
DLco levels<60% of predicted. 
The effect of emphysema, an increase of 0.55 in the FVC/DLco ratio, represented an 
average rise of 34.8% from the observed mean value of 1.58.  On correction of 
equation heteroscedasticity (with logarithmic transformation of the FVC/DLco ratio), 
these findings were robust at the same level of significance, apart from the presence 
of PH (p<0.01).  When the model was examined separately according to smoking 
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status, the impact of emphysema on the FVC/DLco ratio was very similar in smokers 
(RC = 0.56, 95% CI = 0.36, 0.77; p<0.0005) and in non-smokers (RC = 0.49; 95% CI 
0.28, 0.70; p<0..0005).  The confounding effect of the presence of emphysema on the 
FVC/DLco ratio, after adjustment for the extent of disease on HRCT, is shown in 
Figure 3.  
On logistic regression, the independent determinants of an FVC/DLco ratio >2.0 were 
extent of disease on HRCT (odds ratio [OR] = 1.05; 95% CI 1.03, 1.07; p<0.0005), 
the presence of emphysema (OR = 13.8; 95% CI 5.8, 32.8; p<0.0005), increasing age 
(OR = 1.04; 95% CI 1.01, 10.7; p<0.01) and the presence of pulmonary hypertension 
(OR = 2.58; 95% CI 1.12, 5.92; p=0.02). These findings were largely unchanged 
when analysis was confined to 211 patients with DLco levels<60% of predicted, 
although the independent linkage between PH on echocardiography and 
FVC/DLco>2.0 was no longer significant (p=0.06). 
DISCUSSION 
The combination of emphysema and fibrosis, also known as the CPFE syndrome, has 
been reported in patients with CTD-ILD (9).  However, the clinical significance of 
this proposed syndrome has yet to be established.  We report a prevalence of 
emphysema of 12% in a large cohort of SSc-ILD patients, with emphysema present 
more often in current or former smokers but also ssen in 7.5% of life-long non-
smokers.  The presence of emphysema had a significant confounding effect on 
measures of gas transfer and gas exchange in both smokers and non-smokers. The 
FVC/DLco ratio, recently advocated as an important screening tool for pulmonary 
hypertension, was strikingly influenced by the presence of emphysema. 
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The current study of the prevalence and functional impact of emphysema in a 
population of over 300 SSc-ILD patients extends and refines the observations of 
Cottin et al in a series of 34 CTD-ILD patients with CPFE, including 10 with SSc-
ILD (9).  In small cohorts, emphysema had been observed in a handful of non-
smoking patients with rheumatoid lung (14) and SSc-ILD (9).  The size of the current 
cohort allows the confident conclusion to be drawn that emphysema has a significant 
prevalence (7.5%, 95% confidence intervals 4-12%) in non-smokers with SSc-ILD.  
Furthermore, the presence of emphysema in smokers with SSc-ILD was associated 
with a low pack-year smoking history, as also reported in rheumatoid lung (when 
compared with a control cohort of smokers without interstitial lung disease) (14).  
The size of the current cohort allows the confident conclusion to be drawn that 
emphysema has a significant prevalence (7.5%, 95% confidence intervals 4-12%) 
in non-smokers with SSc-ILD.  Furthermore, in smokers with SSc-ILD with an 
average smoking history of only 15 pack-years, emphysema was present in 15%.  
Taken together, these observations raise the possibility that SSc-ILD may be a 
risk factor for the development of emphysema in both smokers and non-
smokers.  However, without a control group of smokers without interstitial lung 
disease, our findings are inconclusive in this regard.  
Given the high prevalence of emphysema in non-smokers, it was important to 
consider the possible confounding effect of inter-observer variability with regard to 
the presence of trivial emphysema.  However, the extent of emphysema did not differ 
between smokers and non-smokers.  More importantly, the presence of emphysema in 
non-smokers had the same effect on measures of gas transfer and gas exchange as in 
smokers.  For a given extent of fibrosis, the presence of emphysema was associated 
14 
 
with a reduction in DLco of over 10% in both smokers and non-smokers.  Strikingly, 
the FVC/DLco ratio rose, on average, by over 40% from the observed values in both 
smokers and non-smokers with emphysema, after adjustment for other variables.  
Given the major functional effects associated with emphysema in non-smokers, 
despite the relatively limited extent of emphysema, it appears difficult to argue that 
our findings have been materially affected by methodological limitations or inter-
observer variability. 
The reported pattern of functional impairment in patients with combined emphysema 
and fibrosis has consisted of relative preservation of lung volumes and a 
disproportionate reduction in DLco levels (8-9,15-17). In most reports, the relative 
impact of concurrent emphysema on lung volumes and measures of gas transfer has 
not been quantified definitively (i.e. with the extent of fibrosis also taken into account 
in multivariate analysis).  However, in the current study, as in an early IPF study (18), 
the presence of emphysema had a much greater effect on DLco levels than FVC levels 
(which were not significantly affected).  These findings suggest that the presence of 
emphysema is unlikely to confound the accurate use of FVC in prognostic evaluation, 
as in an SSc-ILD staging system (19) recently validated against survival (20). By 
contrast, the lack of relative preservation in FVC levels in patients with 
emphysema is likely to reflect the fact that spirometric volumes are influenced by 
smoking-related intrinsic airway inflammation, in a larger smoking patient sub-
group, irrespective of the presence or absence of emphysema.   
  
Our observations indicate that the presence of emphysema has a major confounding 
effect on the contribution of pulmonary function tests to non-invasive screening for 
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PH in SSc-ILD.  Functional abnormalities typically seen in PH include undue hypoxia 
(21) and reductions in DLco that are disproportionate to lung volumes, quantified 
historically by adjustment of DLco for alveolar volume (DLco/VA, Kco) and more 
recently by the FVC/DLco ratio (22).  In SSc, an increased FVC/DLco ratio, alone or 
in combination with other variables, has provided justification for the performance of 
a right heart study, based on thresholds of 1.6 (4-5,7) or 2.0 (6).  
However, in routine practice, pulmonary physiologic profiles suggestive of PH 
generally lead to the performance of echocardiography rather than immediate right 
heart catheterisation, a sequence reproduced in the recent prospective two-step 
DETECT algorithm (23). In that study, the FVC/DLco ratio was validated against 
echocardiographic data and was found to be one of the two non-invasive variables 
most strongly predictive of echocardiographic PH.  However, the DETECT algorithm 
was developed in SSc in general and has not been tested specifically in SSc-ILD.  
Therefore, we report the first evaluation of the accuracy of the FVC/DLco ratio 
against echocardiographic data in SSc-ILD, with particular reference to the presence 
or absence of concurrent emphysema. Echocardiographic criteria for PH in the current 
study were essentially those validated in the DETECT study against the presence of 
PH at right heart catheterisation.  Taken together, the prevalence of emphysema in 
SSc-ILD in the current study, the major confounding effect of emphysema on 
physiologic variables and the importance of the FVC/DLco ratio in the DETECT 
algorithm have prompted us to conclude that the DETECT algorithm may need to be 
adapted in patients with SSc-ILD.  One important proviso is that this needs to be done 
in smokers and non-smokers alike.  Based on our findings, it appears that major 
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increases in the FVC/DLco ratio are not indicative of a high likelihood of PH on 
echocardiography, when emphysema is present on HRCT.   
Given the aims of the current study, our findings have only indirect implications with 
regard to pathogenetic linkages between emphysema and interstitial lung disease in 
SSc.  However, the predilection for the development of emphysema in smoking and 
non-smoking patients with SSc-ILD was striking, taking into account the low pack-
year history associated with emphysema in smokers.  A number of candidate 
pathways are common to emphysema and interstitial lung disease, including oxidative 
stress (24-25), matrix remodeling (26-27), protein citrullination (28-30), elastin 
activation (31-32) and telomerase regulation (33).  There is also the intriguing 
possibility that autoimmune pathways might be implicated both in CTD-ILD and in 
the pathogenesis of emphysema, accounting for the existence of emphysema in some 
non-smokers with SSc-ILD.  Evidence of immune dysregulation has emerged in 
chronic obstructive pulmonary disease cohorts (34-35), including dysfunction of T 
regulatory cells and dendritic cells (36), autoantibody expression (32) and systemic 
manifestations compatible with autoimmunity (37).   
One limitation of the current study is the fact that patients underwent right heart 
catheterisation only if the echocardiographic findings were suggestive of PH.  The 
acquisition of right heart data in all cases would have allowed FVC/DLco thresholds 
to be evaluated for sensitivity, specificity and predictive values against proven PH.  
However, it is doubtful that such a protocol in a large cohort of SSc-ILD patients is 
achievable.  It can also be argued that examination against echocardiography is a 
relevant evaluation of the true clinical utility of the FVC/DLco ratio, which may lie 
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in the selection of patients for echocardiography: a view cardinal to the construction 
of the DETECT algorithm.   
In principle, the use of echocardiography to evaluate the presence of PH in 
patients with emphysema might be confounded by hyperinflation, causing 
difficulty in obtaining clear images of regurgitant flow. However, difficulties in 
measuring echocardiographic variables in non-extensive emphysema have not 
been reported   
 We stress that we cannot exclude the possibility that the relatively high prevalence of 
emphysema in non-smokers in SSc-ILD might apply equally to SSc patients without 
interstitial lung disease.  The nature of our cohort, which consisted of consecutive SSc 
patients with known or suspected lung involvement, did not allow this possibility to 
be explored.  Given the referral pattern to our institution, it was considered highly 
unlikely that the relatively small subset of patients without interstitial lung disease 
were representative of the larger non-referred SSc population.  We suggest that 
further evaluations based on our findings might usefully be undertaken in SSc cohorts 
not selected for the presence of lung involvement.  However, a powerful argument 
against a major excess of emphysema in the absence of interstitial lung disease is the 
finding that the FVC/DLco ratio was, in fact, strongly linked to echocardiographic 
evidence of PH in the whole SSc cohort evaluated in the DETECT study.   
In conclusion, we report a predilection to emphysema in SSc-ILD, as shown by its 
sporadic presence in non-smokers and a low associated pack-year smoking history in 
smokers.  The significance prevalence of emphysema in non-smokers with SSc-ILD 
provides indirect support for a pathogenetic basis for a syndrome of CPFE.  The 
CPFE syndrome is associated with disproportionate impairment of measures of gas 
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transfer and gas exchange, including a major confounding effect on the FVC/DLco 
ratio.  These findings have major implications for the construction of accurate 
screening algorithms for PH in SSc-ILD.   
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Table 1:  Baseline data compared between patients with CPFE and patients 
without emphysema and non-smokers.  CPFE patients were more often male 
smokers, and were characterized, lower DLco and po2 levels and a higher 
FVC/DLco ratio.    [Abbreviations: ILD = interstitial lung disease; PH = 
pulmonary hypertension {as judged by echocardiography)]. 
 CPFE (n=41) Pulmonary fibrosis 
without emphysema 
(n=292) 
Significance 
Age (years) 53.1 + 15.1  54.4 + 12.8  p = 0.57 
Gender (M;F ratio) 18/74 (males 24%)  23/259 (males 9%)  p<0.0005 
Ever-smokers 26/41 (63%) 106/292 (36%) p = 0.001 
ATA positivity (n=308) 14/39 (36%) 127/269 (47%) p = 0.19 
Extent of ILD Median 24.5% (1 – 70%) Median 15.5% (1 – 84%) p = 0.08 
Prevalence of PH (n=311) 9/37 (24%) 38/236 (16.0%) p = 0.10 
FEV1 (% predicted) 73.6 + 18.9  75.3 + 19.6 p = 0.59 
FVC (% predicted) 77.0 + 22.3  75.7 + 21.8  p = 0.73 
DLco (% predicted) 37.8 + 13.0  53.3 + 17.8  p<0.0005 
FVC/DLco ratio Median 2.07  
(1.14 – 3.42) 
Median 1.42  
(0.73 – 3.55) 
p<0.0005 
pO2 (kpa) [n=282] 10.8 + 1.9  11.7 + 1.7  p<0.005 
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Table 2:  Baseline data compared between current or former smokers and non-
smokers.  Smokers were characterized by older age, an increase in the male to female 
ratio, a higher prevalence of emphysema, a higher FVC/DLco ratio, higher 
spirometric volumes and lower po2 levels.    [Abbreviations: ILD = interstitial lung 
disease; PH = pulmonary hypertension {as judged by echocardiography)]. 
 
 Current/ex-smokers  
(n=132) 
Lifelong non-smokers 
(n=201) 
Signficance 
Age (years) 57.2 + 11.4  52.2 + 13.7  p<0.001 
Gender (M;F ratio) 48:84 (males 36%)  26:175 (males 15%)  p<0.001 
Extent of ILD  Median 15% (1 – 84%) Median 18% (1 – 77.5%) p=0.14 
Prevalence of emphysema n = 26 (19.7%)  n = 15 (7.5%)  p<0.001 
Prevalence of PH (n=311) n = 19 (15.2%) n = 28 (15.0%) p=0.95 
FEV1 (% predicted) 78.5 + 20.0  72.9 + 18.9  p<0.01 
FVC (% predicted) 80.6 + 23.1  72.8 + 20.5  p<0.01 
DLco (% predicted) 50.7 + 17.9  51.8 + 18.1  p=0.59 
FVC/DLco ratio Median 1.53 (0.79 – 3.40) Median 1.43 (0.73 – 3.55) p<0.001 
pO2 (kpa) [n=282] 11.1 + 1.9  11.8 + 1.6  p<0.01 
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Table 3:  The independent effects of the extent of interstitial lung disease, smoking 
status and the presence of emphysema on individual pulmonary function variables are 
shown, with adjustment for age and gender.    Effects are expressed as regression 
coefficients (per unit change in the extent of ILD and as a global effect in current or 
former smokers, compared to life-long non-smokers, and for the presence of 
emphysema) with 95% confidence intervals in parentheses and p values.  
[Abbreviations: ILD = interstitial lung disease; Aa gradient = alveolar-arterial oxygen 
gradient]. 
 Extent of ILD Smoker                   
(vs non-smoker) 
Emphysema 
present  
Equation R2 
FEV1 -0.31 (-0.44, -0.19)   
p<0.0005 
4.3 (0.0, 8.7)   
p<0.05 
-0.5 (-6.7, 5.7) 
p=0.87 
0.14 
FVC -0.43 (-0.56, -0.30);   
p<0.0005 
6.0 (1.4, 10.6);   
p=0.01 
3.6 (-3.0, 10.2) 
p=0.29 
0.22 
DLco -0.58 (-0.68, -0.48);  
p<0.0005 
- 0.8 (-4.2, 2.7);   
p=0.66 
-12.4 (-17.3, -7.5) 
p<0.0005 
0.37 
pO2 -0.04 (-0.05, -0.03);   
p<0.0005 
-0.26 (-0.63, 0.11);   
p=0.16 
-0.53 (-1.02, -0.02) 
p=0.04  
0.36 
Aa 
gradient 
0.04 (0.03, 0.05);   
p<0.0005 
0.40 (0.01, 0.78);   
p=0.04 
0.67 (0.15, 1.19) 
p=0.01 
0.32 
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Table 4: Determinants of FVC/DLCO ratio.  Effects are expressed as regression 
coefficients with 95% confidence intervals and p values.   
 Extent of ILD Emphysema 
present 
Pulmonary  
Hypertension 
Smoking status 
FVC/DLCO RC = 0.009;  
95% CI 0.006,-0.011;  
p<0.0005 
 
RC=0.55; 
95% CI 0.41,0.69; 
p<0.0005 
RC=0.25; 
95% CI 0.11,-0.38; 
p<0.0005 
RC=0.13; 
95% CI 0.03,-0.22; 
p<0.01 
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Figure legends 
Figure 1:  DLco levels are shown in relation to the extent of disease on HRCT.  
Patients with emphysema (n = 41, closed circles) are compared to patients without 
emphysema (n = 295, open circles).  The presence of emphysema had a significant 
effect on DLco levels with, on average, a reduction in DLco of 12.7% (i.e. 
approximately 25% of baseline levels) after adjustment for the extent of interstitial 
lung disease.     
 
Figure 2:  FVC levels are shown in relation to the extent of disease on HRCT.  
Patients with emphysema (n = 41, closed circles) are compared to patients without 
emphysema (n = 295, open circles).  The presence of emphysema did not have a 
significant effect on FVC levels. 
 
Figure 3:  The FVC/DLco ratio is shown in relation to the extent of disease on 
HRCT.  Patients with emphysema (n = 41, closed circles) are compared to patients 
without emphysema (n = 295, open circles).  The presence of emphysema had a 
significant effect on the FVC/DLco ratio with, on average, an increase of 0.57 (i.e. 
approximately 35% of baseline levels), after adjustment for the extent of interstitial 
lung disease, age and the presence of pulmonary hypertension, as judged by 
echocardiography.     
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